共 163 条
[1]
Siegel RL(2023)Cancer statistics, 2023 CA Cancer J Clin 73 17-48
[2]
Miller KD(2014)A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) J Thorac Oncology: Official Publication Int Association Study Lung Cancer 9 154-62
[3]
Wagle NS(2011)Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 735-42
[4]
Jemal A(2005)National Cancer Institute of Canada Clinical Trials G. Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123-32
[5]
Shi Y(2022)Addition of Bevacizumab to Erlotinib as First-Line treatment of patients with EGFR-Mutated Advanced Nonsquamous NSCLC: the BEVERLY Multicenter Randomized Phase 3 Trial J Thorac Oncology: Official Publication Int Association Study Lung Cancer 17 1086-97
[6]
Au JS(2019)Erlotinib plus Bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial Lancet Oncol 20 625-35
[7]
Thongprasert S(2003)Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes Annals Oncology: Official J Eur Soc Med Oncol 14 511-9
[8]
Srinivasan S(2004)Management of anemia in patients with cancer Curr Oncol Rep 6 297-304
[9]
Tsai CM(2020)Severe megaloblastic anemia: vitamin deficiency and other causes Cleve Clin J Med 87 153-64
[10]
Khoa MT(2016)RECIST 1.1-Update and clarification: from the RECIST committee Eur J cancer (Oxford England: 1990) 62 132-7